Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
The related Athira compound fosgonimeton failed its Phase 2 Alzheimer's trial (LIFT-AD) in 2023 for efficacy, and Athira discontinued development
PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation
Kalm M, Fukuda A, Fukuda H et al (2009) Transient inflammation in neurogenic regions after irradiation of the developing brain
282(j)(5)(C)(ii), requesting that results of its Phase 2 clinical trial of a treatment for acne rosacea be submitted to the ClinicalTrials.gov data bank (after first contacting the company about the issue in October 2020)
US$ 24.03
US$ 28.76
US$ 27.89
